EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Niagen Bioscience's Enterprise Value is $208.6 Mil.
Niagen Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $4.1 Mil. Therefore, Niagen Bioscience's EV-to-FCF for today is 50.79.
The historical rank and industry rank for Niagen Bioscience's EV-to-FCF or its related term are showing as below:
NAGE'
s EV-to-FCF Range Over the Past 10 Years
Min: -78.86 Med: -9.03 Max: 268.97
Current: 50.79
During the past 13 years, the highest EV-to-FCF of Niagen Bioscience was 268.97. The lowest was -78.86. And the median was -9.03.
NAGE's EV-to-FCF is ranked worse than 78.01% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs NAGE: 50.79
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Niagen Bioscience's PE Ratio (TTM) for today is calculated as:
Niagen Bioscience's share price for today is $3.42.
Niagen Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Niagen Bioscience EV-to-FCF Related Terms
Niagen Bioscience EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Niagen Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's EV-to-FCF falls into.
Niagen Bioscience's current Enterprise Value is $208.6 Mil.
Niagen Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (NAGE) has a EV-to-FCF of 50.79 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Niagen Bioscience and its competitors. According to the industry distribution chart, Niagen Bioscience ranks #259 out of 332 companies in the Biotechnology industry, placing it in the top 78%.
Is Niagen Bioscience's EV-to-FCF too high?
Niagen Bioscience's current EV-to-FCF is 50.79. The Biotechnology industry median EV-to-FCF is 16.26. Niagen Bioscience's value of 50.79 is 212.4% above this industry median. Based on the distribution chart, Niagen Bioscience ranks #259 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Niagen Bioscience has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's EV-to-FCF compare to ARMP and ALXO?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #259 out of 332 companies for EV-to-FCF. This places Niagen Bioscience in the lower half of its industry. The industry median EV-to-FCF is 16.26. Niagen Bioscience's value of 50.79 is 212.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niagen Bioscience's current EV-to-FCF of 50.79 is 212.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Niagen Bioscience and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current EV-to-FCF is 50.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (NAGE) is currently considered Possible Value Trap. The stock's GF Value™ is $5.04, compared to a current price of $3.42 — trading 32.1% below its estimated fair value. The current EV-to-FCF is 50.79 and 212.4% above the Biotechnology industry median of 16.26. Niagen Bioscience's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Niagen Bioscience (NAGE), the current EV-to-FCF is 50.79 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (NAGE) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of $3.42 is trading 32.1% below its estimated GF Value™ of $5.04.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for NAGE:
EV-to-FCF: 50.79
GF Value™: $5.04 vs. price of $3.42 (32.1% below fair value)
Industry Position: 212.4% above the Biotechnology median (#259 of 332)
No single metric tells the full story. See the NAGE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
68GF Score
Get the complete analysis for NAGE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAGE has been successfully added to your 
